Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Gogoro Inc (GGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Gogoro Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Gogoro Inc trades at $3.93 (market cap $76.98M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 104.4× Gogoro Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals.
| BIO | GGR | |
|---|---|---|
Market Cap | $8.04B | $76.98M |
Sector | Health | Technology |
52-Week High | $339.75 | $7.89 |
52-Week Low | $241.71 | $2.74 |
Enterprise Value | $7.85B | $379.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
GGR trades at $3.88, up 0.78% on the day, while showing bearish technical signals with a negative net income margin of -24.68% and ROE of -50.38% for 2025. The company reported revenue of $281.48M but a net loss of $79.97M, though cash flow from operations improved to $35.90M. Recent news highlights a private placement and Q1 2026 results emphasizing margin improvement and growth plans.
Outlook remains challenged by persistent losses and negative profitability metrics, offset by operational discipline and subscriber growth. Key risks include execution on profitability, competitive pressures, and cash flow sustainability. Analysts are neutral with 100% hold ratings, reflecting cautious optimism amid fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →
